Indegene Q3 results: Revenue surges 31% to ₹942 crore but profit, margins dip

Indegene reported a mixed performance in the third quarter of FY26, with net profit declining even as revenue and operating earnings posted strong growth.

Net profit for the quarter fell 6.2% year-on-year to ₹102.9 crore, compared with ₹109 crore in the same period last year.

Revenue surged 30.8% to ₹942 crore from ₹720 crore a year ago, reflecting robust topline momentum. EBITDA rose 21.9% year-on-year to ₹159.9 crore, up from ₹131.2 crore in the corresponding quarter of the previous year.

However, operating margin narrowed to 17% from 18.2% a year earlier, indicating some pressure on profitability despite higher revenues.

This quarter delivered its first $100 million-plus revenue, driven by  client momentum and AI-led productivity gains, the company stated.

Also Read: Carborundum Universal Q3 profit more than doubles despite lower margins; dividend declared

Chairman and CEO Manish Gupta said revenue per employee crossed $70,000 annually while three customers crossed the $25-million annual revenue mark and 52 customers exceeded $1-million in annual revenues.

CFO Suhas Prabhu said, “During the quarter, we completed the acquisitions

of BioPharm, a US-focused life sciences omnichannel business, and Warn & Co, a UK-based consulting firm — that deepen our domain expertise and expand our high-value capabilities."

He added, "Our cash and investments are a healthy ₹13,954 million (₹1,395.4 crore), net of acquisition outflows, with continued cash generation strengthening our balance sheet."

The company said the notification of the four labour codes in November 2025, which consolidate 29 existing labour laws, has no material impact on its financial results, based on its current assessment.

Also Read: Who controls critical minerals could control the energy transition: Economic Survey 2026

Shares of Indegene Ltd slipped 1.39% to ₹469 on the NSE in Thursday’s trade, down ₹6.60.